Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
12,812 people get MRK articles and Market Currents by email alert.
Get email alerts on MRK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Merck's Liptruzet: A Cause For Shame?Derek Lowe • Thu, May 9 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call TranscriptFri, Apr 27, 2012
-
Merck & Co. Inc. - Special CallThu, Nov 10, 2011
-
Merck & Co.'s CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Merck & Co.'s CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Merck & Co.'s CEO Discusses Q1 2011 Results - Earnings Call TranscriptFri, Apr 29, 2011
-
Merck CEO Discusses Q3 2010 Results - Earnings Call TranscriptFri, Oct 29, 2010
-
Merck & Co. Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Merck & Co. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Merck & Co., Inc. Q4 2009 Earnings Call TranscriptTue, Feb 16, 2010
-
Merck & Co., Inc. Q3 2009 Earnings Call TranscriptThu, Oct 22, 2009
-
Merck & Co. Inc. Q2 2009 Earnings Call TranscriptTue, Jul 21, 2009
-
Merck F1Q09 Earnings Call TranscriptTue, Apr 21, 2009
-
at CNBC.com (Wed, 4:08PM)
-
at CNBC.com (Wed, 9:57AM)
-
at CNBC.com (Wed, 8:06AM)
-
at MarketWatch.com (Tue, 4:59PM)
-
at CNBC.com (Tue, 4:51PM)
-
at MarketWatch.com (Tue, 4:37PM)
-
at CNBC.com (Tue, 4:07PM)
-
at CNBC.com (Mon, 6:26PM)
-
at MarketWatch.com (Mon, 4:38PM)
-
at CNBC.com (May 17, 2013)
-
Business Wire (May 15, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 2, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at Fox Business (May 1, 2013)
MRK vs. ETF Alternatives
Company Description
On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation (“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger, Schering-Plough acquired all of the shares of Old Merck, which became a wholly-owned subsidiary of Schering-Plough... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 16, 2011, 3:45 PM Merck (MRK +0.8%) shares rise on the company's FDA approval to launch a new hepatitis C drug after evaluating the safety and effectiveness of the treatment in two phase-3 clinical trials. Rival Vertex (VRTX -0.4%) also awaits FDA approval of its new hepatitis C drug later this month, but one analyst believes Merck should capture 20-30% of the global market hepatitis C market. Comment! [Healthcare]
- Thursday, May 12, 2011, 4:49 PM News that treating AIDS patients with antiretroviral drugs makes them much less infectious helps efforts to slow the disease’s spread as well as the companies making those drugs. Abbott Labs (ABT +0.9%), Bristol-Myers Squibb (BMY +0.5%), Gilead Sciences (GILD +1.3%), GlaxoSmithKline (GSK +1.1%) and Merck (MRK +1.6%) were all higher today. Comment! [Healthcare]
- Tuesday, May 3, 2011, 8:34 AM Nasdaq (NDAQ) and NYSE Arca (NYX) canceled bad after-hour trades in over 50 stocks, including in Pfizer (PFE) and Merck (MRK). A source said the trades, which were mostly in healthcare stocks, were made in a purchase of an entire portfolio of shares that were sold together, as in a basket. 1 Comment
- Friday, April 29, 2011, 7:56 AM Merck (MRK) +1.8% after beating earnings estimates. The company's pharmaceutical, animal health and consumer care divisions all contributed solid revenue growth, with earnings also helped by cost-control measures. Comment! [Healthcare, Earnings, On the Move]
- Friday, April 29, 2011, 7:22 AM Merck (MRK): Q1 EPS of $0.92 beats by $0.08. Revenue of $11.58B (+1.4% Y/Y) beats by $0.22B. Shares +1.51% premarket. (PR) Comment! [Earnings, Healthcare]
- Friday, April 29, 2011, 12:05 AM Notable earnings before Friday's open: AIV, AON, CAT, CPN, CVX, DHI, ETR, GT, ITT, LEA, MRK, NEE, NVE, NWL, PBI, SPG, TOT, WY Comment! [Earnings]
- Thursday, April 28, 2011, 4:44 PM FDA panel unanimously endorses Vertex's (VRTX) hepatitis C drug, telaprevir, noting a cure rate jump to 80% from 40% with current therapies. This follows yesterday's approval of Merck's (MRK) boceprevir - which had only a 60-65% cure rate. Shares to resume at 4:50. Comment! [Healthcare, On the Move]
- Tuesday, April 26, 2011, 1:54 PM Shares of Vertex Pharmaceuticals (VRTX +10.8%) surge to a 52-week high after the U.S. Food & Drug Administration says that Vertex's hepatitis C drug telaprevir successfully treats the majority of patients with the virus in less time than other established medicines. Tomorrow, the FDA will post a review of a similar drug from Merck (MRK +2.2%). Comment! [Healthcare, On the Move]
- Friday, April 15, 2011, 2:10 PM These 10 U.S. companies have the most untaxed foreign income: 1. GE at $94B, 2. PFE at $48B, 3. MRK, 4. JNJ, 5. XOM, 6. C, 7. CSCO, 8. IBM, 9. PG, 10. MSFT. Comment! [U.S. Economy]
-
Friday, April 15, 2011, 9:00 AM
Premarket gainers: AGO +19%. MBI +14%. AMLN +12%. PMI +9%. BRNC +7%. MPEL +6%. RDN +5% ABMD +5%. CDE +5%. MTG +5%. MRK +3%.
Losers: INFY -11%. ABAT -10%. CRUS -6%. GOOG -5%. URBN -3%. Comment! [On the Move] - Friday, April 15, 2011, 8:55 AM Merck (MRK) +3.1% premarket after inking a deal with Johnson & Johnson (JNJ) that ends their dispute over the distribution of Remicade and Simponi. Instead of a previous 50/50 split, MRK will now receive 58% of sales, and pay JNJ a $500M one-timer. (PR) Comment! [Healthcare, On the Move]
- Friday, April 15, 2011, 7:52 AM J&J (JNJ) and Merck (MRK +2%) reach a new distribution deal for Remicade and Simponi, ending a pending arbitration hearing between the two drug companies. (PR) Comment! [Healthcare, On the Move]
- Tuesday, April 12, 2011, 7:32 AM Late Monday, the FDA approved the use of Merck's (MRK) Sylatron drug to treat skin cancer in patients with node-positive melanoma following the removal of the affected part. (PR) Comment! [Healthcare]
- Tuesday, April 5, 2011, 9:37 AM Merck (MRK -0.4%) says it will acquire Inspire Pharmaceuticals (ISPH), a developer of ophthalmic products, in an all-cash deal for $5/share, or ~$430M. The offer represents a 26% premium to yesterday's closing price. Trading in ISPH halted. (PR) Comment!
- Thursday, March 24, 2011, 2:25 PM Amgen (AMGN +1%) may introduce its first dividend at an April 21 investor meeting, Bloomberg says, boosting a stock whose value has been chopped by a third since 2006. Unlike other biotechs, Amgen can afford to return money to shareholders because it generates a lot of cash compared with capital expenditures. But the projected 2.3% yield would rank well behind drugmakers PFE, MRK and JNJ. 1 Comment
- Tuesday, March 22, 2011, 7:36 AM Abandoning their planned animal health JV is a blow to Merck (MRK) and Sanofi (SNY) as they try to scale up in a consolidating industry. It's also a blow to smaller firms eager to buy assets Sanofi/Merck would have been forced to shed. The winner here is Pfizer Animal Health (PFE) which will retain its top spot in the market. 1 Comment
-
- View all 0 replies
-
Philip Davis
Philstockworld Wrap-Up Show - $IWM, $DIA, $USO, $GLL, $CMG, $DUG, $MRK: http://bit.ly/i8iMWI - View all 0 replies
-
James Hofman
Merck (MRK) has been taking a beating the last few weeks. The move is way over done. I am a buyer at these prices.. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES